(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02. Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
At the Company's Board of Directors' meeting held on May 17, 2017, the Board approved an increase in the dollar value of the annual equity grants for non-employee directors from $150,000 to $170,000. All cash compensation arrangements remain the same. This resulted in the need for an additional grant of 3,472 shares of restricted stock to Luis Aguilar, who recently joined the Board in March 2017, to bring his compensation in line with the other non-employee directors.
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On May 17, 2017, MiMedx Group, Inc. held its 2017 Annual Meeting. There were two proposals acted upon at the meeting. All nominees for director were elected (Proposal 1) and Proposal 2 was approved. The following is a description of each item and the votes cast for each:
Proposal 1: The election of directors
For
Against
Abstain
Broker Non votes
Charles R. Evans
51,011,858
75,691
71,493
38,925,674
Charles E. Koob
45,887,932
5,216,382
54,728
38,925,674
Neil
S. Yeston
50,611,028
465,416
82,598
38,925,674
Luis A. Aguilar
50,993,754
76,622
88,666
38,925,674
Proposal
2: Proposal to ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the current fiscal year.
For
Against
Abstain
Total shares voted
88,814,205
652,337
618,174
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.